Having trouble accessing articles? Reset your cache.

Progenics chronicles

Progenics chronicles

Progenics' stock has had a bumpy ride from the newsflow related to the methylnaltrexone compound it in-licensed from UR Labs in 2001. The company ended last week up 95% - gaining $6.52 to $13.40 - on FDA

Read the full 381 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE